Endocrine therapy (ET) with tamoxifen (TAM) or aromatase inhibitors (AI) is highly effective against hormone receptor–positive (HR-positive) early breast cancer (BC), but resistance remains a major challenge. This evidence concerns the gene NR4A1 and breast carcinoma.